Comparison of dsRNA Adjuvants—PIC, PICLC, PIC12U and PICKCa®

作者: 林海祥 * , 李烈涛 , 张 译 :北京依生兴业科技有限公司,北京;

关键词: 双链RNA疫苗佐剂皮卡dsRNA Vaccine Adjuvant PICKCa

双链RNA佐剂包括PIC、PICLC、PIC12U和皮卡(PICKCa®),是多种膜式识别受体(TLR3、NOD、MAD-5和RID-1)的配体,熔点分别是PIC 57℃,PICKCa 80℃,PICLC 91℃。由于灵长目以上动物血清核酸酶对双链RNA的降解,前两种佐剂对猴和人体或者效果差或者副作用大,且美国FDA在2012年也把PIC12U否决了,而我们研制的皮卡佐剂(PICKCa®)弥补了其它dsRNA佐剂的不足,对灵长类动物和人安全有效。

Abstract: dsRNA adjuvants include PIC, PICLC, PIC12U (Trade name Ampligen) and PICKCa® (PIC-kanamycin- Cacl2). They are ligands of varied pattern recognition receptorsTLR3, NOD, MAD-5 and RID-1. The melt points are 57˚C for PIC, 80˚C for PICKCa, 91˚C for PICLC respectively. Because of the degradation of double stranded RNA in the serum of primates and above, The first two kinds of adjuvants have poor effects or severe side effect to the monkey and human. PIC12U was also denied by US FDA in 2012, while PICKCa overcomes shortcomings of PIC, PICLC and PIC12U and it is safe and effective for monkey and human.

文章引用: 林海祥 , 李烈涛 , 张 译 (2015) 双链RNA(dsRNA)佐剂的比较——PIC、PICLC、PIC12U、PICKCa®。 自然科学, 3, 127-136. doi: 10.12677/OJNS.2015.34017


[1] Richmond, J.Y., Hamilton, L.D. (1969) Foot-and-Mouth Disease Virus Inhibition Induced in Mice by Synthetic Double-Stranded RNA (Polyriboinosinic and Polyribocytidylic Acids). Proceedings of the National Academy of Sciences of the United States of America, 64, 81-86.

[2] Thomson, A.W. (1977) The Influence of Poly I: Poly C on Kinetics of the Primary Immune Response to Sheep Erythrocytes in the Mouse Spleen. Biomedicine, 26, 319-326.

[3] Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., et al. (2006) Essential Role of MDA-5 in Type I IFN Responses to Polyriboinosinic: Polyribocytidylic Acid and Encephalomyocarditis Picornavirus. Proceedings of the National Academy of Sciences of the United States of America, 103, 8459-8464.

[4] Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., et al. (2006) Differential Roles of MDA5 and RIG-I Helicases in the Recognition of RNA Viruses. Nature, 441, 101-105.

[5] Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S., et al. (2005) Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection. Journal of Virology, 79, 2910- 2919.

[6] Partidos, C.D., Hoebeke, J., Moreau, E., Chaloin, O., Tunis, M., Belliard, G., et al. (2005) The Binding Affinity of Double-Stranded RNA Motifs to HIV-1 Tat Protein Affects Transactivation and the Neutralizing Capacity of Anti-Tat Antibodies Elicited after Intranasal Immunization. European Journal of Immunology, 35, 1521-1529.

[7] Sloat, B.R. and Cui, Z.R. (2006) Nasal Immunization with a Dual Antigen Anthrax Vaccine Induced Strong Mucosal and Systemic Immune Responses against Toxins and Bacilli. Vaccine, 24, 6405-6413.

[8] Pulko, V., Liu, X., Krco, C.J., Harris, K.J., Frigola, X., Kwon, E.D. and Dong, H.D. (2009) TLR3-Stimulated Dendritic Cells Up-Regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination. The Journal of Immunology, 183, 3634-3641.

[9] Carrie, A.J., van der Most, R.G., Broomfield, S.A., Prosser, A.C., Tovey, M.G. andRobinson, B.W.S. (2008) Targeting the Effector Site with IFN-αβ-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors. The Journal of Immunology, 180, 1535-1544.

[10] Nordlund, J.J., Wolff, S.M. and Levy, H.B. (1970) Inhibition of Biologic Activity of Poly I: Poly C by Human Plasma. Proceedings of the Society for Experimental Biology and Medicine, 133, 439-444.

[11] McFarling, D.E., Bever, C.T., Salazar, A.M., et al. (1985) A Preliminary Trial of Poly(IC)-LC in Multiple Sclerosis. Journal of Biological Response Modifiers, 4, 544-548.

[12] Robinson, R.A., De Vita, V.T., Levy, H.B., et al. (1976) A Phase I-II Trial of Multiple-Dose Poliriboinosic Acid-Po- lyribocytidylic Acid in Patients with Leukemia or Solid Tumors. Journal of the National Cancer Institute, 57, 599- 602.

[13] Levy, H.B., Baer, G., Baron, S., Buckler, C.E., Gibbs, C.J., et al. (1975) A Modified Polyriboinosinic-Polyribocyti- dylic Acid Complex that Induces Interferon Inprimates. Journal of Infectious Diseases, 132, 434-439.

[14] Sammons, M.L., Stephen, E.L., Levy, H.B., Baron, S. and Hilmas, D.E. (1977) Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrobial Agents and Chemotherapy, 11, 80-83.

[15] Sahl-Hennig, C., Eisenblatter, M., Jasny, E., et al. (2009) Synthetic Double-Stranded RNAs Are Adjuvant for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques. PLoS Pathogens, 5, e1000373.

[16] Levy, H.B., London, W., Fuccillo, D.A., Baron, S. and Rice, J. (1976) Prophylactic Control of Simian Hemorrhagic Fever in Monkeys by an Interferon Inducer, Polyriboinosinic-Polyribocytidylic Acid-Poly-L-Lysine. Journal of Infectious Diseases, 133, A256-A259.

[17] Stephen, E.L., Sammons, M.L., Pannier, W.L., Baron, S., Spertzel, R.O., et al. (1977) Effect of a Nuclease-Resistant Derivative of Polyriboinosinic-Polyribocytidylic Acid Complex on Yellow Fever in Rhesus Monkeys (Macaca mulatta). Journal of Infectious Diseases, 136, 122-126.

[18] Puri, S.K., Dutta, G.P., Levy, H.B. and Maheshwari, R.K. (1996) Poly ICLC Inhibits Plasmodium cynomolgi B Malaria Infection in Rhesus Monkeys. Journal of Interferon & Cytokine Research, 16, 49-52.

[19] Houston, W.E., Crabbs, C.L., Stephen, E.L. and Levy, H.B. (1976) Modified Polyriboinosinic-Polyribocytidylic Acid, an Immunological Adjuvant. Infection and Immunity, 14, 318-319.

[20] Stephen, E.L., Hilmas, D.E., Mangiafico, J.A. and Levy, H.B. (1977) Swine Influenza Virus Vaccine: Potentiation of Antibody Responses in Rhesus Monkeys. Science, 197, 1289-1290.

[21] 侯云德, 吴淑华, 编. 干扰素[M]. 北京: 人民卫生出版社, 1981: 108-111.

[22] Carter, W.A., Pitha, P.M., Marsall, L.W., et al. (1972) Structural Requirements of the rln•rCn Complex for Induction of Human Interferon. Journal of Molecular Biology, 70, 567-587.

[23] Ichinohe, T., Tamura, S., Kawaguchi, A., Ninomiya, A., Imai, M., et al. (2007) Cross Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine. Journal of Infectious Diseases, 196, 1313-1320.

[24] Ichinohe, T., Kawaguchi, A., Tamura, S., Takahashi, H., Sawa, H., et al. (2007) Intranasal Immunization with H5N1 Vaccine plus Poly I: Poly C12U, a Toll-Like Receptor Agonist, Protects Mice against Homologous and Heterologous Virus Challenge. Microbes and Infection, 9, 1333-1340.

[25] Thompson, K.A., Strayer, D.R., Salvato, P.D., Thompson, C.E., Klimas, N., et al. (1996) Results of a Double-Blind Placebo-Controlled Study of the Double-Stranded RNA Drug Poly I: Poly C12U in the Treatment of HIV Infection. European Journal of Clinical Microbiology & Infectious Diseases, 15, 580-587.

[26] Adans, M., Navabi, H., Jasani, B., et al. (2003) Dendritic Cell (DC) Based Therapy for Cervical Cancer: Use of DC Pulsed with Tumour Lysate and Matured with a Novel Synthetic Clinically Non-Toxic Double Strainded RNA Analogue Poly I: Poly C12U (Ampligen R). Vaccine, 21, 787-790.

[27] Navabi, H., Jasani, B., Reece, A., et al. (2009) A Clinical Grade Poly I: C-Analogue (Ampligen) Promotes Optimal DC Maturation and Th1-Type T Cell Responses of Healthy Donors and Cancer Patients in Vitro. Vaccine, 27, 107-115.

[28] Brodsky, I., Strayer, D.R., Krueger, L.J., et al. (1985) Clinical Studies with Ampligen (Mismatched Double-Stranded RNA). Journal of Biological Response Modifiers, 4, 669-675.

[29] Carter, W.A., Strayer, D.R., Hubbell, H.R., et al. (1985) Preclical Studies with Ampligen (Mismatched Double- Stranded RNA). Journal of Biological Response Modifiers, 4, 495-502.

[30] US FDA Response Letter Regarding Approval of Ampligen for ME/CFS, 2012.

[31] 宗建超. 聚肌胞(PIC)研究回顾[C]// 中国微生物学会. 全国第五次干扰素学术会议论文集. 西安, 1985: 23-28.

[32] Lin, H.X., Gontier, C., Saron, M.-F., et al. (1993) A New Immunostimulatory Complex (PICKCa) in Experimental Rabies: Antiviral and Adjuvant Effects. Archives of Virology, 131, 307.

[33] 林海祥, 俞永新. 皮卡佐剂狂犬病疫苗的有效性[J]. 中国生物制品学杂志, 2010(9): 1028-1031.

[34] 李茂光, 俞永新, 李加, 等. Poly IC佐剂狂犬病疫苗诱导小鼠的免疫应答[J]. 中国生物制品学杂志, 2010(8): 852- 856.

[35] 林海祥, 俞永新. 皮卡佐剂狂犬病疫苗的安全性[J]. 中国生物制品学杂志, 2010(1): 98-100.

[36] Shen, E.X. and Wu, C.Y. (2007) PIKA as an Adjuvant Enhances Specific Humoral and Cellular Immune Responses Following the Vaccination of Micee with HBsAg plus PIKA. Cellular & Molecular Immunology, 4, 11.

[37] Lau, Y.F., Tang, L.-H., Ooi, E.E. and Subbarao, K. (2010) Activation of the Innate Immune System Provides Broad- Spectrum Protection against Influenza A Viruses with Pandemic Potential in Mice. Virology, 406, 80-87.

[38] Lau, Y.-F., Tang, L.-H. and Ooi, E.-E. (2009) A TLR3 Ligand that Exhibits Potent Inhibition of Influenza Virus Replication and Has Strong Adjuvant Activity Has the Potential for Dual Applications in an Influenza Pandemic. Vaccine, 27, 1354-1364.

[39] Tang, L.-H., Lim, J.H., Kuah, L.F., et al. (2014) Compete Protection against Lethal Challenge of Novel H7N9 Virus with Heterologous Inactevated H7 Vaccine in Mice. Vaccine, 32, 5375-5378.

[40] Gai, W.-W., Zhang, Y., Zhou, D.-H., et al. (2011) PIKA Provides an Adjuvant Effect to Induce Strong and Systemic Humoral Immunity against SARS-CoV. Virologica Sinica, 26, 81-94.

[41] 林海祥, Perrin, P. 铝佐剂对实验狂犬病疫苗的影响[J]. 中华实验和临床病毒学杂志, 1999(2): 133-135.

[42] 聚肌胞注射液国家药品标准. WS1-XG-050-2000.

[43] 杜平, 叶天星. 现代抗病毒制剂的临床应用[M]. 上海: 上海科学技术出版社, 1992: 203.

[44] 中华人民共和国药典2010版三部: 人用狂犬病疫苗(地鼠肾细胞), 115-118.

[45] 杨进业, 谢艺红, 莫兆军, 等. 广西狂犬病早死现象的研究[J]. 广西预防医学杂志, 2005(3): 143-146.

[46] 张永振, 肖东楼, 孙玉辉, 等. 中国1984-2002年狂犬病流行情况和防制对策[J]. 中华流行病学杂志, 2003(10): 883-886.

[47] 朱凤才, 祖荣强, 吴扬生, 等. 江苏省1990-2000年狂犬病流行情况和防制策略[J]. 中华流行病学杂志, 2001(1): 14-16.

[48] 王树声. 一种新型的皮卡治疗性(PIKA)佐剂狂犬病疫苗——抢救生命的治性疫苗[J]. 应用预防医学, 2010(1): 1-4.